Abstract
In order to overcome the significant side effects and the acquired resistance of platinum-based anticancer drugs, great efforts have been devoted to designing new platinum compounds or non-platinum transition metal anticancer complexes with improved pharmacological properties and a broader range of antitumor activity. Among them, the new complexes based on natural alkaloid and their derivatives provide a novel approach to potential (pro-)drugs. This review was mainly focused on the recent progresses of alkaloid-metal based anticancer agents, including metal complexes of natural or synthetic alkaloids, liriodenine, β-carboline, and quinolinoline as anticancer agents, their in vitro anticancer activities and primary action mechanism. Additionally, the future development of hybrid alkaloid and its derivatives metal complexes as anticancer drugs was discussed, which might hold a promise for overcoming multidrug resistance (MDR).
Keywords: Alkaloid, liriodenine, β-carboline alkaloid, quinolinoline, anticancer agents, metal complexes.
Current Topics in Medicinal Chemistry
Title:Alkaloid-Metal Based Anticancer Agents
Volume: 13 Issue: 17
Author(s): Zhen-Feng Chen, Yan-Cheng Liu, Ke-Bin Huang and Hong Liang
Affiliation:
Keywords: Alkaloid, liriodenine, β-carboline alkaloid, quinolinoline, anticancer agents, metal complexes.
Abstract: In order to overcome the significant side effects and the acquired resistance of platinum-based anticancer drugs, great efforts have been devoted to designing new platinum compounds or non-platinum transition metal anticancer complexes with improved pharmacological properties and a broader range of antitumor activity. Among them, the new complexes based on natural alkaloid and their derivatives provide a novel approach to potential (pro-)drugs. This review was mainly focused on the recent progresses of alkaloid-metal based anticancer agents, including metal complexes of natural or synthetic alkaloids, liriodenine, β-carboline, and quinolinoline as anticancer agents, their in vitro anticancer activities and primary action mechanism. Additionally, the future development of hybrid alkaloid and its derivatives metal complexes as anticancer drugs was discussed, which might hold a promise for overcoming multidrug resistance (MDR).
Export Options
About this article
Cite this article as:
Chen Zhen-Feng, Liu Yan-Cheng, Huang Ke-Bin and Liang Hong, Alkaloid-Metal Based Anticancer Agents, Current Topics in Medicinal Chemistry 2013; 13 (17) . https://dx.doi.org/10.2174/15680266113139990146
DOI https://dx.doi.org/10.2174/15680266113139990146 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Current Organic Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Signal Transduction Pathways of Taxanes-Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Histidine Rich Glycoprotein, an Endogenous Regulator of Macrophage and Endothelial Biology
Current Angiogenesis (Discontinued) A Validated Mathematical Model of Tumour-Immune Interactions for Glioblastoma
Current Medical Imaging Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Recent Advances in Optical Molecular Imaging and its Applications in Targeted Drug Delivery
Current Drug Targets